A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma

BACKGROUND: TOURMALINE-MM1 was a global study that demonstrated a significant improvement in progression-free survival with ixazomib plus lenalidomide and dexamethasone compared with placebo plus lenalidomide and dexamethasone, in patients with relapsed and/or refractory multiple myeloma. The curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Iida, Shinsuke, Izumi, Tohru, Komeno, Takuya, Terui, Yasuhito, Chou, Takaaki, Ikeda, Takashi, Berg, Deborah, Fukunaga, Shinichi, Sugiura, Kenkichi, Sasaki, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732884/
https://www.ncbi.nlm.nih.gov/pubmed/34599726
http://dx.doi.org/10.1007/s10147-021-02030-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732884/
https://www.ncbi.nlm.nih.gov/pubmed/34599726
http://dx.doi.org/10.1007/s10147-021-02030-7

Ejemplares similares